The modern biopharmaceutical industry traces its roots to the dawn of the twentieth century,
coincident with marketing of aspirin—a signature event in the history of modern drug …

This review provides insight into the role of engineered T-cell receptors (TCRs) in
immunotherapy. Novel approaches have been developed to boost anticancer immune …

INTRODUCTION TP53 (tumor protein P53), a tumor suppressor gene, is the most commonly
mutated cancer-driver gene. Nevertheless, drugs that target mutant p53, the protein product …

Purpose: Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a
melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain …

Mutations in the RAS oncogenes occur in multiple cancers, and ways to target these
mutations has been the subject of intense research for decades. Most of these efforts are …

Neoantigens derived from somatic mutations are specific to cancer cells and are ideal
targets for cancer immunotherapy. KRAS is the most frequently mutated oncogene and …

Metastatic disease from uveal melanoma occurs in almost 50% of patients suffering from this
ocular tumour, with median survival from development of symptoms being around 1 year. In …

Disruption of splicing patterns due to mutations of genes coding splicing factors in tumors
represents a potential source of tumor neoantigens, which would be both public (shared …

ABSTRACT A bispecific antibody (bsAb) is able to bind two different targets or two distinct
epitopes on the same target. Broadly speaking, bsAbs can include any single molecule …

Background Because of the shortage of ideal cell surface antigens, the development of T-
cell receptor (TCR)-engineered T cells (TCR-T) that target intracellular antigens such as NY …